Accesibilidad a la farmacoterapia específica de la enfermedad de Parkinson, en Santiago de Chile / Accessibility of patients with Parkinson disease to specific pharmacotherapy in Chile
Rev. méd. Chile
;
126(11): 1355-61, nov. 1998. tab
Article
Dans Espagnol
| LILACS
| ID: lil-243728
ABSTRACT
Background:
The high costs of adequate pharmacological treatment for Parkinson disease preclude the universal access of patients to this medication.Aim:
To assess the accessibility to pharmacological treatment of Chilean patients with Parkinson disease. Patients andmethods:
An inquiry about socioeconomic stratification, medical controls, disease features and costs of pharmacological therapy, was applied to 95 patients (56 male, aged 32 to 89 years old) attending the Chilean League Against Parkinson Disease.Results:
Among studied patients, the disease had a mean duration of 7.9ñ6 years. There was a direct relationship between family income, the frequency of visits to physicians and the dose and cost of pharmacological therapy.Conclusions:
The accessibility to pharmacological therapy among patients with Parkinson disease, depends on their socioeconomic level. Measures to correct this situation and improve the quality of life of these patients should be undertaken by health services
Recherche sur Google
Indice:
LILAS (Amériques)
Sujet Principal:
Maladie de Parkinson
/
Antiparkinsoniens
Limites du sujet:
Adulte
/
Femelle
/
Humains
/
Mâle
Pays comme sujet:
Amérique du Sud
/
Chili
langue:
Espagnol
Texte intégral:
Rev. méd. Chile
Thème du journal:
Médicament
Année:
1998
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS